Search Results
Your search for ,Non matches 5542 pages
Showing 1201 - 1250Financial Hardship and Risk Factors in Patients With Cancer Receiving Routine Clinical Care
In a study reported in JCO Oncology Practice, Voleti et al identified the proportion of patients with cancer receiving routine clinical care who reported financial hardship and analyzed risk factors for financial hardship. The researchers found that patients who reported experiencing financial...
Qinjin Fan, PhD, on Equitable Lung Cancer Care and Mortgage Discrimination
Qinjin Fan, PhD, of the American Cancer Society, explores the question of how mortgage discrimination is linked to lower rates of guideline-concordant care for patients with non–small cell lung cancer. This study highlights the critical need to understand the pathways through which mortgage denials ...
Managing Lymphomas in the Future: Some Bright Spots Are Emerging
Although standard therapies may provide long-lasting remissions for many patients with various subtypes of lymphoma, there is a critical need for new strategies for the sizable high-risk subset. At the 2022 Pan Pacific Lymphoma Conference, four experts in the field described future therapies for...
Expert Point of View: Mary O’Brien, MD
Formal discussant of the KEYNOTE-189 and KEYNOTE-407 trials, Mary O’Brien, MD, Head of the Lung Unit, Royal Marsden Hospital, NHS Foundation Trust, London, found that both studies showed consistent gains in overall and progression-free survival with pembrolizumab/chemotherapy, but she expressed...
5-Year Follow-up Supports Survival Benefit of Pembrolizumab Plus Chemotherapy in Squamous and Nonsquamous NSCLC
Pembrolizumab (anti–PD-1 therapy) plus chemotherapy continued to demonstrate a survival benefit and durable responses as first-line treatment of metastatic non–small cell lung cancer (NSCLC), according to the results of two phase III trials.1,2 Five-year overall survival was improved in both...
Expert Point of View: Suzette Delaloge, MD, MSc
Formal discussant of this study, Suzette Delaloge, MD, MSc, of Gustave Roussy, Villejuif, France, stated: “This is a big step forward and an amazing set of new knowledge. This presentation is a meaningful demonstration of the role of PM2.5 [particulate matter 2.5 µm in diameter] air pollutants in...
Mechanism Linking Air Pollution to Lung Cancer Identified
Although air pollution is associated with lung cancer, not much has been known about how one leads to the other. For the first time, researchers have identified a mechanism by which particulate matter in the air triggers non–small cell lung cancer (NSCLC) in people who have never smoked. Moreover,...
What Is the Best Induction Regimen for Newly Diagnosed PCNSL?
Primary central nervous system lymphoma (PCNSL) accounts for less than 1% of all non-Hodgkin lymphomas and between 3% and 4% of all brain tumors, with an age-adjusted incidence rate of four cases per million persons per year. Approximately 1,500 new cases are diagnosed each year in the United...
The Development of Geriatric Oncology in France: An Outside View
With the aging of the world population, geriatric oncology is becoming a mainstay. Over the past year in The ASCO Post, we published a couple of articles on the history of oncology, including one on the history of geriatric oncology in the United States and Europe. Our goal was to promote a...
Expert Point of View: Hisashi Saji, MD
Abstract discussant Hisashi Saji, MD, Chair of Thoracic Surgery at St. Marianna University School of Medicine, Kawasaki, Japan, said that, based on two recently reported phase III studies, sublobar resection, including wedge resection and segmentectomy, must be considered as a standard of care for...
Sublobar Resection for Small, Early-Stage NSCLC: Establishing a New Standard of Care?
After a nearly 20-year wait, the results are finally in: sublobar surgery has been found to be noninferior to lobectomy and may be the new standard of care of patients with small, early-stage non–small cell lung cancer (NSCLC). Results of the phase III Alliance trial, presented at the International ...
Medicaid Expansion and Palliative Care Use Among Patients Newly Diagnosed With Advanced Cancer
Recent data showed that Medicaid expansion may be associated with increased use of palliative care among newly diagnosed individuals with stage IV cancer, although overall usage of palliative care was low. In addition, the increase after Medicaid expansion varied by cancer type, according to a...
Historical Housing Discrimination May Adversely Affect Contemporary Colon Cancer Care and Outcomes
Recent findings showed that historical housing discrimination may negatively affect contemporary care and outcomes for patients diagnosed with colon cancer, according to a study by Hussaini et al in the Journal of Clinical Oncology. The findings were also presented at the 2022 ASCO Quality Care...
Is Mortgage Discrimination Adversely Associated With Receipt of Guideline-Concordant NSCLC Care?
Findings reported by researchers from the American Cancer Society (ACS) and Johns Hopkins University showed that area-level mortgage discrimination may be adversely associated with receipt of guideline-concordant care among patients with non–small cell lung cancer (NSCLC) in the United States,...
Real-World Experience With Durvalumab at the Mayo Clinic Mirrors PACIFIC Trial Findings
Concurrent chemoradiation therapy followed by durvalumab has become the standard of care in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC), based on the PACIFIC trial.1 However, clinical trials have predetermined inclusion and exclusion criteria, and they evaluate...
Real-World Evidence Confirms Survival Benefit of Durvalumab in Locally Advanced Non–Small Cell Lung Cancer
In locally advanced non–small cell lung cancer (NSCLC), immunotherapy consolidation with the PD-L1 inhibitor durvalumab improved overall survival in the PACIFIC trial,1 thus leading to its use after chemoradiotherapy as a standard of care. Real-world evidence of durvalumab’s effect on overall and...
Expert Point of View: Benjamin Besse, MD, PhD
Discussant of the IMpower010 abstract, Benjamin Besse, MD, PhD, Professor and Head of Clinical Research at Institute Gustave Roussy, Villejuif, France, said there is enough evidence to use adjuvant immunotherapy in stage II–IIIA resected non–small cell lung cancer (NSCLC), calling the increased...
IMpower010: Early Survival Data Favor Atezolizumab Over Best Supportive Care in Resected NSCLC With PD-L1 Expression ≥ 50%
Early results from the IMpower010 trial showed an overall survival trend favoring adjuvant atezolizumab vs best supportive care for patients with PD-L1–positive (tumor expression ≥ 1%), stage II–IIIA (UICC/AJCC staging system, 7th ed), resected non–small cell lung cancer (NSCLC). These data were...
Highlights From the IASLC 2022 World Conference on Lung Cancer
Over the past few years, we have seen rapid and dramatic transformation in the therapeutic landscape of non–small cell lung cancer (NSCLC). We have had multiple new targeted therapies for newer targets (previously undruggable targets) and better diagnostic strategies to workup patients to realize...
DART Trial: Concurrent Radiotherapy Plus Durvalumab Active in Older Patients With Locally Advanced Lung Cancer
Interim results of a phase II study have demonstrated the safety and feasibility of treating elderly and frail patients with locally advanced non–small cell lung cancer (NSCLC) with the monoclonal antibody durvalumab during and after radiation therapy, without chemotherapy. The results of a...
Expert Point of View: Corinne Faivre-Finn, MD, PhD, and Masahiro Tsuboi, MD
The first discussant of the NADIM II study, Corinne Faivre-Finn, MD, PhD, Professor of Thoracic Radiation Oncology, University of Manchester, and Honorary Consultant Clinical Oncologist at The Christie NHS Foundation Trust, Manchester, England, called the results “very impressive” but noted that...
NADIM II Trial: Neoadjuvant Chemoimmunotherapy Improved Survival in Resectable, Stage IIIA NSCLC
In patients with resectable, stage IIIA non–small cell lung cancer (NSCLC), the addition of neoadjuvant nivolumab to platinum-based chemotherapy significantly improved overall survival compared with neoadjuvant chemotherapy alone, according to data presented by Mariano Provencio, MD, PhD, at the...
Exploratory Analysis of POSEIDON: Chemoimmunotherapy Regimen May Offer Survival Benefit in Subgroups of Patients With Metastatic NSCLC
The addition of the CTLA-4 inhibitor tremelimumab to durvalumab and chemotherapy in the first-line setting has already demonstrated an overall survival and progression-free survival benefit vs chemotherapy alone in patients with metastatic non–small cell lung cancer (NSCLC). According to data...
Selpercatinib in RET Fusion–Positive Advanced NSCLC
As reported in the Journal of Clinical Oncology by Alexander Drilon, MD, and colleagues, an updated analysis of the multicohort phase I/II LIBRETTO-001 trial confirmed the activity of selpercatinib in patients with RET fusion–positive advanced non–small cell lung cancer (NSCLC). The trial supported ...
Risks Associated With Sinoatrial Node Radiation Dose in Patients With Lung Cancer Receiving Definitive Chemoradiotherapy
In a Korean single-institution retrospective cohort study reported in JAMA Oncology, Kim et al found that higher sinoatrial node radiation doses were associated with an increased risk of atrial fibrillation and poorer survival in patients with limited-stage small cell lung cancer (SCLC) and locally ...
Extended-Interval vs Standard-Interval Dosing of Single-Agent Pembrolizumab
In a retrospective cohort study performed in U.S. veterans reported in JAMA Oncology, Strohbehn et al found that a minority of patients receiving singe-agent pembrolizumab for cancer received the extended-interval dosing of 400 mg every 6 weeks. Analysis of efficacy measured as the time to...
Tissue vs ctDNA NGS for Detecting Actionable Alterations in Patients With Advanced Cancer
A large prospective analysis, published by Bayle et al in Annals of Oncology, evaluated differences between tissue and circulating tumor DNA (ctDNA) next-generation sequencing (NGS) with a large cancer gene panel. The investigators compared the impacts of both methods in terms of molecular tumor...
FDA Approves Biosimilar Bevacizumab-adcd for the Treatment of Six Types of Cancer
On September 28, the U.S. Food and Drug Administration (FDA) approved bevacizumab-adcd (Vegzelma), a biosimilar to bevacizumab (Avastin), for the treatment of six types of cancer: metastatic colorectal cancer; recurrent or metastatic nonsquamous non–small cell lung cancer (NSCLC); recurrent...
Report Emphasizes Continued Access to Fertility Preservation Is Critical for AYAs With Cancer Following SCOTUS Decision
The Supreme Court of the United States (SCOTUS) ruling in Dobbs v Jackson overruled Roe v Wade, returning an individual’s right to access abortion services to state law. New findings led by researchers at the American Cancer Society published by Jiang et al in The Lancet Oncology showed that more...
Treatment of Non–Clear Cell RCC
This is Part 4 of Updates in Renal Cell Carcinoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Wenxin (Vincent) Xu, David Braun, and Bradley McGregor discuss the treatment of non–clear cell renal cell carcinoma (RCC). The...
Therapeutic Universal Cancer Peptide–Based Vaccine in Refractory Advanced NSCLC
In a French phase Ib/IIa trial reported in the Journal of Clinical Oncology, Adotévi et al found that a therapeutic universal cancer peptide–based vaccine (UCPVax) induced specific CD4+ T helper–1 responses in many patients with refractory advanced non–small cell lung cancer (NSCLC), with...
Genomic Testing May Aid in Identifying Patients of African Descent With High-Risk Prostate Cancer
Black patients of African descent tend to be diagnosed more frequently with prostate cancer and have higher mortality rates than patients of other races and ethnicities. Despite this substantial disparity, few prospective studies focused on maximizing the recruitment of African American patients...
Exercise Therapy Across the Cancer Care Continuum
Guest Editor’s Note: Several studies have shown that regular physical activity helps to reduce the symptom burden and improve disease-related outcomes in patients with cancer. In this article, Jessica M. Scott, PhD, and Neil M. Iyengar, MD, summarize the current evidence surrounding exercise...
Changing the Algorithm for Relapsed or Refractory Large B-Cell Lymphomas
Despite a significant potential for cure, relapsed and refractory large B-cell lymphomas (LBCL) comprise the most common cause of lymphoma-related mortality. Sequential relapses reflect the limits of repeated exposure to chemotherapy, even when delivered at high doses. More than 30 years ago,...
Exploratory Analysis of POSEIDON: Chemoimmunotherapy Regimen May Offer Survival Benefit in Subgroups of Metastatic NSCLC
The addition of the CTLA-4 inhibitor tremelimumab to durvalumab and chemotherapy in the first-line setting has already demonstrated an overall survival and progression-free survival benefit vs chemotherapy alone in patients with metastatic non–small cell lung cancer (NSCLC). According to data...
Patients With Multiple Myeloma May Face CAR T-Cell Shortages
From microchips to automobiles, people in the United States are experiencing shortages of all kinds of products, and oncology treatments are no exception. In particular, shortages related to chimeric antigen receptor (CAR) T-cell therapy have been reported, most acutely, for B-cell maturation...
Trastuzumab Deruxtecan for Advanced HER2-Mutant NSCLC
On August 11, 2022, fam-trastuzumab deruxtecan-nxki was granted accelerated approval for unresectable or metastatic non–small cell lung cancer (NSCLC) with tumors that have activating HER2 mutations, as detected by a U.S. Food and Drug Administration (FDA)-approved test and who have received a...
Capmatinib for Metastatic NSCLC With MET Exon 14 Skipping Mutation
On August 10, 2022, capmatinib was granted regular approval for patients with metastatic non–small cell lung cancer (NSCLC) with tumors having a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by a U.S. Food and Drug Administration–approved test.1...
Practice-Changing Studies, Important New Data, and More Clinical Oncology News From ESMO 2022, Paris
The European Society For Medical Oncology (ESMO) launched its annual congress, held September 9–13, 2022, just as this issue of The ASCO Post was going to press. Watch upcoming issues for comprehensive coverage of the live congress, following 2 years of virtual meetings and remote presentations due ...
Expert Point of View: Benjamin Besse, MD, PhD
Discussant of the IMpower010 abstract, Benjamin Besse, MD, PhD, Professor and Head of Clinical Research at Institute Gustave Roussy, Villejuif, France, said there is enough evidence to use adjuvant immunotherapy in stage II–IIIA resected non–small cell lung cancer (NSCLC), calling the increased...
IMpower010: Early Survival Data Favor Atezolizumab Over Best Supportive Care in Resected NSCLC With PD-L1 Expression ≥ 50%
Early results from the IMpower010 trial showed an overall survival trend favoring adjuvant atezolizumab vs best supportive care for patients with PD-L1–positive (tumor expression ≥ 1%), stage II–IIIA (UICC/AJCC staging system, 7th ed), resected non–small cell lung cancer (NSCLC). These data were...
Expert Point of View: Corinne Faivre-Finn, MD, PhD and Masahiro Tsuboi, MD
The first discussant of the NADIM II study, Corinne Faivre-Finn, MD, PhD, Professor of Thoracic Radiation Oncology, University of Manchester, and Honorary Consultant Clinical Oncologist at The Christie NHS Foundation Trust, Manchester, England, called the results “very impressive” but noted that...
NADIM Trial: Neoadjuvant Chemoimmunotherapy Improved Survival in Resectable, Stage IIIA NSCLC
In patients with resectable, stage IIIA non–small cell lung cancer (NSCLC), the addition of neoadjuvant nivolumab to platinum-based chemotherapy significantly improved overall survival compared with neoadjuvant chemotherapy alone, according to data presented by Mariano Provencio, MD, PhD, at the...
Selpercatinib in RET Fusion–Positive Solid Tumors Other Than Lung or Thyroid Malignancies
As reported in The Lancet Oncology by Vivek Subbiah, MD, and colleagues, the phase I/II LIBRETTO-001 basket trial has shown that the RET kinase inhibitor selpercatinib demonstrated activity in patients with RET fusion–positive solid tumors in an analysis excluding lung and thyroid cancers. Findings ...
Adjuvant Pembrolizumab in Patients With Completely Resected Stage IB to IIIA NSCLC
As reported in The Lancet Oncology by O’Brien et al, the second interim analysis of the phase III PEARLS/KEYNOTE-091 trial has shown significantly improved disease-free survival with adjuvant pembrolizumab vs placebo in patients with completely resected stage IB to IIIA non-small cell lung cancer...
Selpercatinib Approved for Locally Advanced or Metastatic RET Fusion–Positive Solid Tumors
On September 21, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selpercatinib (Retevmo) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion and disease progression on or following prior systemic...
FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion–Positive NSCLC
On September 21, the U.S. Food and Drug Administration (FDA) granted regular approval to selpercatinib (Retevmo) for adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with a RET gene fusion (as detected by an FDA-approved test). The FDA also approved the Oncomine ...
Housing Instability and Risk of Mortality in Patients With Cancer
Little is known about patients with cancer’s social welfare and how it affects their health outcomes. To address this, researchers at University of California (UC) San Diego School of Medicine and partnering institutions assessed the prevalence and impact of various social risk factors in patients...
Neoadjuvant Atezolizumab May Be Safe, Effective Option for Localized Non–Small Cell Lung Cancer
New data show that the immuno-oncology drug atezolizumab may be a safe and effective treatment for patients with stage IB to IIIB non–small cell lung cancer (NSCLC) prior to surgery, according to a study led by researchers with The Ohio State University Comprehensive Cancer Center–Arthur G. James...
Individuals of Mexican Descent May Have Higher Risk of Liver Cancer With Each Successive Generation
Studies show that Hispanic individuals have higher incidence rates of developing liver cancer and higher mortality rates—by 50% or more—than non-Hispanic White individuals for several cancers, including liver cancer. A new study investigating hepatocellular carcinoma among successive generations of ...
